Tela Bio Inc
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue… Read more
Tela Bio Inc (TELA) - Total Assets
Latest total assets as of September 2025: $61.59 Million USD
Based on the latest financial reports, Tela Bio Inc (TELA) holds total assets worth $61.59 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tela Bio Inc - Total Assets Trend (2017–2024)
This chart illustrates how Tela Bio Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Tela Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Tela Bio Inc's total assets of $61.59 Million consist of 89.4% current assets and 10.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 60.3% |
| Accounts Receivable | $10.10 Million | 11.6% |
| Inventory | $12.78 Million | 14.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.74 Million | 2.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Tela Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tela Bio Inc's current assets represent 89.4% of total assets in 2024, a decrease from 92.4% in 2017.
- Cash Position: Cash and equivalents constituted 60.3% of total assets in 2024, down from 73.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 14.6% of total assets.
Tela Bio Inc Competitors by Total Assets
Key competitors of Tela Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Tela Bio Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Tela Bio Inc generates 0.79x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Tela Bio Inc is currently not profitable relative to its asset base.
Tela Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.30 | 2.62 | 12.60 |
| Quick Ratio | 2.62 | 1.81 | 12.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $39.07 Million | $ 27.27 Million | $ 76.62 Million |
Tela Bio Inc - Advanced Valuation Insights
This section examines the relationship between Tela Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 25.29 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | 11.9% |
| Total Assets | $87.33 Million |
| Market Capitalization | $14.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tela Bio Inc's assets below their book value (0.16 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Tela Bio Inc's assets grew by 11.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tela Bio Inc (2017–2024)
The table below shows the annual total assets of Tela Bio Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $87.33 Million | +11.89% |
| 2023-12-31 | $78.05 Million | +15.02% |
| 2022-12-31 | $67.86 Million | +8.49% |
| 2021-12-31 | $62.54 Million | -27.66% |
| 2020-12-31 | $86.46 Million | +27.29% |
| 2019-12-31 | $67.92 Million | +149.47% |
| 2018-12-31 | $27.23 Million | +75.30% |
| 2017-12-31 | $15.53 Million | -- |